Product Name
SPG20, siRNA
Full Product Name
SPG20 siRNA (Human)
Product Synonym Names
KIAA0610; TAHCCP1; Spartin; Spastic paraplegia 20 protein; Trans-activated by hepatitis C virus core protein 1
Product Gene Name
SPG20 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q8N0X7
Specificity
SPG20 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human SPG20 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of SPG20 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
SPG20 sirna
siRNA to inhibit SPG20 expression using RNA interference
Applications Tested/Suitable for SPG20 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for SPG20. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001135766.1
[Other Products]
NCBI GenBank Nucleotide #
NM_001142294.1
[Other Products]
UniProt Primary Accession #
Q8N0X7
[Other Products]
UniProt Secondary Accession #
O60349; Q86Y67; Q9H1T2; Q9H1T3[Other Products]
UniProt Related Accession #
Q8N0X7[Other Products]
Molecular Weight
72,833 Da
NCBI Official Full Name
spartin
NCBI Official Synonym Full Names
spastic paraplegia 20 (Troyer syndrome)
NCBI Official Symbol
SPG20??[Similar Products]
NCBI Official Synonym Symbols
SPARTIN; TAHCCP1
??[Similar Products]
NCBI Protein Information
spartin
UniProt Protein Name
Spartin
UniProt Synonym Protein Names
Spastic paraplegia 20 protein; Trans-activated by hepatitis C virus core protein 1
UniProt Gene Name
SPG20??[Similar Products]
UniProt Synonym Gene Names
KIAA0610; TAHCCP1??[Similar Products]
UniProt Entry Name
SPG20_HUMAN
NCBI Summary for SPG20
This gene encodes a protein containing a MIT (Microtubule Interacting and Trafficking molecule) domain, and is implicated in regulating endosomal trafficking and mitochondria function. The protein localizes to mitochondria and partially co-localizes with microtubules. Stimulation with epidermal growth factor (EGF) results in protein translocation to the plasma membrane, and the protein functions in the degradation and intracellular trafficking of EGF receptor. Multiple alternatively spliced variants, encoding the same protein, have been identified. Mutations associated with this gene cause autosomal recessive spastic paraplegia 20 (Troyer syndrome). [provided by RefSeq, Nov 2008]
UniProt Comments for SPG20
SPG20: May be implicated in endosomal trafficking, or microtubule dynamics, or both. Defects in SPG20 are the cause of spastic paraplegia autosomal recessive type 20 (SPG20); also known as Troyer syndrome (TRS). Spastic paraplegia is a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SPG20 is characterized by dysarthria, distal amyotrophy, mild developmental delay and short stature.
Protein type: Unknown function
Chromosomal Location of Human Ortholog: 13q13.3
Cellular Component: mitochondrial outer membrane; cytoplasm; plasma membrane; synapse; lipid particle; midbody
Molecular Function: protein binding; ubiquitin protein ligase binding
Biological Process: regulation of mitochondrial membrane potential; negative regulation of collateral sprouting in the absence of injury; cell division; neuromuscular process; abscission; negative regulation of BMP signaling pathway
Disease: Spastic Paraplegia 20, Autosomal Recessive
Research Articles on SPG20
1. hypermethylation of the spastic paraplegia-20 promoter occurred frequently in gastric cancer.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
